Panagora Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Panagora Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$625K	Sell	46,982 -346	-0.7%	-$3.37K	﹤0.01%	842
2026 Q1	$441K	Buy	47,328 +349	+0.7%	+$3.04K	﹤0.01%	881
2025 Q4	$352K	Hold	46,979	–	–	﹤0.01%	955
2025 Q3	$408K	Buy	+46,979	New	+$281K	﹤0.01%	863
2024 Q4	–	Sell	-100,973	Closed	-$1.09M	–	1178
2024 Q3	$1.09M	Sell	100,973 -253,884	-72%	-$4.21M	0.01%	704
2024 Q2	$7.45M	Buy	354,857 +252,789	+248%	+$6.34M	0.04%	259
2024 Q1	$3.25M	Sell	102,068 -1,603	-2%	-$40.9K	0.02%	434
2023 Q4	$2.1M	Buy	103,671 +27,983	+37%	+$368K	0.01%	546
2023 Q3	$964K	Buy	+75,688	New	+$1.27M	0.01%	791

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Panagora Asset Management's FDMT Position: Q2 2026 in Review

Panagora Asset Management reduced its 4D Molecular Therapeutics (FDMT) stake by 0.73% in Q2 2026, selling an estimated $3.37K and leaving 46,982 shares worth $625K. The position accounts for ﹤0.01% of the portfolio, ranked #842.

Panagora Asset Management first reported a position in FDMT in Q3 2023 and has held it in 9 quarters since. The position peaked at $7.45M in Q2 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Panagora Asset Management held 46,982 shares of 4D Molecular Therapeutics worth $625K as of Q2 2026.
Panagora Asset Management sold 346 4D Molecular Therapeutics shares in Q2 2026, an estimated $3.37K.
4D Molecular Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #842 holding.
Panagora Asset Management first reported a position in 4D Molecular Therapeutics in Q3 2023 and has held it in 9 quarters since.
Panagora Asset Management's 4D Molecular Therapeutics position peaked at $7.45M in Q2 2024.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.